Details of the Drug Combination

General Information of Drug Combination (ID: DCA9E4W)

Drug Combination Name
SNX-5422 GDC-0084
Indication
Disease Entry Status REF
Hodgkin lymphoma Investigative [1]
Component Drugs SNX-5422   DMIU0VP GDC-0084   DMA9SEY
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: L-428
Zero Interaction Potency (ZIP) Score: 7.571
Bliss Independence Score: 8.754
Loewe Additivity Score: 15.299
LHighest Single Agent (HSA) Score: 5.372

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SNX-5422
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1/2 [2]
Non-small-cell lung cancer 2C25.Y Phase 1/2 [2]
Chronic lymphocytic leukaemia 2A82.0 Phase 1 [2]
Neuroendocrine cancer 2B72.1 Phase 1 [2]
SNX-5422 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [4]
Heat shock protein 90 beta (HSP90B) TTH5YN2 HS90B_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of GDC-0084
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 2 [3]
GDC-0084 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Hodgkin lymphoma DCGG28H HDLM-2 Investigative [1]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03522298) Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma. U.S. National Institutes of Health.
4 SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
5 Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829.